Project Details
Description
MT2024-42: Phase 1b Dose Expansion Study of NXC-201 for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis.
| Status | Active |
|---|---|
| Effective start/end date | 1/23/25 → 1/22/36 |
Funding
- NEXCELLA, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.